(Q53243881)
Statements
Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole. (English)
D Rayson
R Dewar
T Younis
4 January 2007
16
3
252-261